Exscientia presents novel immuno-oncology biomarker for exs-21546 at the esmo i-o annual congress

Vienna, austria & oxford, england--( business wire )--exscientia plc (nasdaq: exai) today highlighted new data to identify patients that are more likely to respond to its a2a receptor antagonist, exs-21546 (‘546) as well as the relationship to potential impact of adenosine on pd-1 inhibitor response. the research identified a novel patient selection multi-gene transcript signature, the adenosine burden score (abs), that will be confirmed in the company's phase 1/2 study, ignite-ai. the data are being presented at the esmo immuno-oncology annual congress, being held december 7-9 in geneva, switzerland.
EXAI Ratings Summary
EXAI Quant Ranking